AUA 2018: Percutaneous Cryoablation of Renal Tumors in Solitary Kidney: Results From an Italian Multicentric Study

San Francisco, CA USA (UroToday.com) Gaetano Chiapparrone from the Urologic Clinic of Azienda Sanitaria Universitaria Integrata di Trieste delivered a podium on their study assessing outcomes when using percutaneous cryoablation (PCA) in patients with a solitary kidney.

To do so, they performed a retrospective review of a multi-institutional database of patients with a solitary kidney and who underwent computed tomography-guided PCA from December 2008 to June 2016.

Their final analytical cohort included 28 patients with a mean age of 70.8 years. Mean body mass index was 27.5. Mean tumor size was 27.4 mm. Renal masses were located posteriorly in 27 patients, had a mean PADUA score of 7.9, and were biopsy-proved renal cell carcinoma in 16 patients. The overall complications rate was 39%, including nine Clavien-Dindo grade 1, one grade 2, and one grade 3. They found no significant difference in renal function pre- and post-PCA. At a mean follow-up of 33.7 months, recurrence-free survival was 88% with recurrence occurring in three patients.

The authors concluded that PCA is a safe and effective treatment modality in patients with a solitary kidney.

Further analysis is warranted once a larger sample size is acquired.

Presented by: Gaetano Chiapparrone

Written by: Michael Owyong, Department of Urology, University of California-Irvine at the 2018 AUA Annual Meeting - May 18 - 21, 2018 – San Francisco, CA USA
email news signup